Avidity Biosciences, Inc.
Avidity Biosciences, Inc.
Your view on RNA
Overview
What the company does, where it operates, and who runs it.
About Avidity Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sarah Boyce
- Headquarters
- 10578 Science Center Drive, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sarah Boyce
- Headquarters
- 10578 Science Center Drive, San Diego, CA, US
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases.
Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Avidity Biosciences, Inc., and the rating behind it. RNA last traded at $10.36; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Avidity Biosciences, Inc.. Starting points for Avidity Biosciences, Inc.: EPS -$5.45, beta 0.37 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Avidity Biosciences, Inc.. Avidity Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Avidity Biosciences, Inc.. Trailing twelve-month EPS for Avidity Biosciences, Inc. stands at -$5.45. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Avidity Biosciences, Inc.. Avidity Biosciences, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Avidity Biosciences, Inc. valued side by side against its closest peers. Avidity Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Avidity Biosciences, Inc., and how their positions are changing. At a $177.2M market value, institutional positions materially move Avidity Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Avidity Biosciences, Inc. executives and directors. Shares of Avidity Biosciences, Inc. have traded between $21.51 and $71.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Avidity Biosciences, Inc.. Avidity Biosciences, Inc. is a $177.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Avidity Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Avidity Biosciences, Inc.. Coverage tracks Avidity Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.